Difference between pharmacokinetics of mycophenolic acid (MPA) in rats and that in humans is caused by different affinities of MRP2 to a glucuronized form

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 10, Issue 1, 2007, Pages 71-85

  Takekuma, Yoh ^a   Kakiuchi, Haruka ^b   Yamazaki, Koujiro ^b   Miyauchi, Seiji ^a   Kikukawa, Takashi ^a   Kamo, Naoki ^a   Ganapathy, Vadivel ^c   Sugawara, Mitsuru ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG PROTEIN BINDING; DRUG UPTAKE; GENETIC CODE; HELA CELL; HUMAN; HUMAN CELL; MALE; MEMBRANE TRANSPORT; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; VOLTAGE CLAMP; XENOPUS LAEVIS;

ANIMALS; BILE; GLUCURONIDES; HELA CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYCOPHENOLIC ACID; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-AMINOHIPPURIC ACID; RATS; RATS, WISTAR; SPECIES SPECIFICITY; XENOPUS LAEVIS;

EID: 34247862333     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995, 17: 681-4
2. Schrem H, Luck R, Becker T, Nashan B, Klempnauer J. Update on liver transplantation using cyclosporine. Transplant Proc 2004, 36: 2525-31
3. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995, 60: 225-32
4. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995, 345: 1321-5
5. Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Marsh JW, McCauley J, Johnston J, Randhawa P, Irish W, Gritsch HA, Naraghi R, Hakala TR, Fung JJ,Starzl TE. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999, 67: 411-5
6. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998, 34: 429-55
7. Johnson AG, Rigby RJ, Taylor PJ, Jones CE, Allen J, Franzen K, Falk MC,Nicol D. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther 1999, 66: 492-500
8. Shum B, Duffull SB, Taylor PJ,Tett SE. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol 2003, 56: 188-97
9. van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD,van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006, 17: 871-80
10. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996, 36: 315-24.
11. Matsuzawa Y, Nakase T. Metabolic fate of ethyl O-[N-(p-carboxyphenyl)-carbamoyl] mycophenolate (CAM), a new antitumor agent, in experimental animals. J Pharmacobiodyn 1984, 7: 776-83.
12. Westley IS, Brogan LR, Morris RG, Evans AM, Sallustio BC. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos 2006, 34: 261-6.
13. Kobayashi M, Saitoh H, Tadano K, Takahashi Y, Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 2004, 309: 1029-35
14. Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K. Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett 1998, 438: 321-4
15. Sekine T, Cha SH,Endou H. The multispecific organic anion transporter (OAT) family. Pflugers Arch 2000, 440: 337-50
16. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T,Endou H. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 2001, 59: 1277-86
17. Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V,Leibach FH. Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem 1995, 270: 25672-7
18. Sugawara M, Mochizuki T, Takekuma Y, Miyazaki K. Structure-affinity relationship in the interactions of human organic anion transporter 1 with caffeine, theophylline, theobromine and their metabolites. Biochim Biophys Acta 2005, 1714: 85-92
19. Fei YJ, Sugawara M, Liu JC, Li HW, Ganapathy V, Ganapathy ME,Leibach FH. cDNA structure, genomic organization, and promoter analysis of the mouse intestinal peptide transporter PEPT1. Biochim Biophys Acta 2000, 1492: 145-54
20. Matsuzawa Y,Nakase T. Metabolic fate of ethyl O-[N-(p-carboxyphenyl)-carbamoyl] mycophenolate (CAM), a new antitumor agent, in experimental animals. J Pharmacobiodyn 1984, 7: 776-83
21. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001, 23: 119-28
22. Pritchard JB,Miller DS. Mechanisms mediating renal secretion of organic anions and cations. Physiol Rev 1993, 73: 765-96
23. Burckhardt BC, Wolff NA,Burckhardt G. Electrophysiologic characterization of an organic anion transporter cloned from winter flounder kidney (fROAT). J Am Soc Nephrol 2000, 11: 9-17
24. Aslamkhan A, Han YH, Walden R, Sweet DH, Pritchard JB. Stoichiometry of organic anion/dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells. Am J Physiol Renal Physiol 2003, 285: F775-83
25. Kuroda M, Kobayashi Y, Tanaka Y, Itani T, Mifuji R, Araki J, Kaito M,Adachi Y. Increased hepatic and renal expressions of multidrug resistance-associated protein 3 in Eisai hyperbilirubinuria rats. J Gastroenterol Hepatol 2004, 19: 146-53
26. Hirohashi T, Suzuki H,Sugiyama Y. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem 1999, 274: 15181-5
27. Ninomiya M, Ito K,Horie T. Functional analysis of dog multidrug resistance-associated protein 2 (Mrp2) in comparison with rat Mrp2. Drug Metab Dispos 2005, 33: 225-32von Mollendorff E, Abshagen U, Akpan W, Neugebauer G, Schroter E. Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity. Clin Pharmacol Ther 1986, 39: 677-82